乌鸦传媒

While all adults age 75 and up are eligible, here's who's considered high risk in the 60-74 group

"Remarkable" how closely effectiveness in real-world setting matches clinical trial efficacy

Another vaccine option, updated ACIP recommendations, and data on a new monoclonal antibody

Decision was based on need for RSV protection in younger people with chronic conditions

However, questions remain about durability of vaccine protection, expert says

Paul Offit, MD, talks about the flu, RSV, and COVID vaccines for the 2024-2025 season

Initial trials were not powered to assess efficacy against RSV-associated hospitalization

Co-administration generally safe, could reduce vaccine burden, researchers say

Committee ditches shared decision-making, moves to risk-based approach

Arexvy now approved for people 50 years and older at increased risk of serious outcomes

But compared with mRNA COVID-19 vaccines, GBS was more common than expected

Moderna vaccine indicated for people ages 60 and up

"Administration errors are preventable with proper education and training," say study authors

New RSV vaccines could reduce risk, researchers said